Background Patients' beliefs about treatment influence treatment engagement and
adherence. The Necessity-Concerns Framework postulates that adherence is influenced by …

The standard approach for documenting symptomatic adverse events (AEs) in cancer
clinical trials involves investigator reporting using the National Cancer Institute's (NCI's) …

The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent
in cancer care. Approximately 25–30% of the oncology drug pipeline involves oral agents …

Importance In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are
reported by investigators rather than by patients. There is increasing interest to collect …

Nonadherence to prescribed pharmacotherapy is an understated public health problem
globally and is costing many patients their chance to return to good health and healthcare …

Introduction: To date, orally administered chemotherapy and biologic agents represent a
significant percentage of all antineoplastic treatments in several types of cancer, which are …

OATP2B1 is an intestinal and hepatic drug uptake transporter. Intestinal OATP2B1 has been
elucidated as the mechanism of unexpected clinical drug–drug interactions (DDIs), where …

Purpose Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-
small cell lung cancer. Understanding actual use of medication is essential for optimizing …

With the recent growth in oral anticancer agents (OAA), pharmacists working in the
community have recognised the urgent need to develop safe and effective systems to …

Objective: Oral antineoplastic agents (OAA) lead to new challenges in patient education,
monitoring, medication errors, drug interactions, adverse events management, and …